De-Run Kong1, Jin-Guang Wang1, Chen Chen1, Fang-Fang Yu1, Qiong Wu1, Jian-Ming Xu1. 1. De-Run Kong, Jin-Guang Wang, Chen Chen, Fang-Fang Yu, Qiong Wu, Jian-Ming Xu, Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.
Abstract
AIM: To explore the effect of intravariceal-mucosal sclerotherapy using small dose of sclerosant on the recurrence of esophageal varices. METHODS: We randomly assigned 38 cirrhotic patients with previous variceal bleeding and high variceal pressure (> 15.2 mmHg) to receiveendoscopic variceal ligation (EVL) and combined intravariceal and esophageal mucosal sclerotherapy (combined group) using small-volume sclerosant. The end-points of the study were rebleeding and recurrence of esophageal varices. RESULTS: During a median follow-up period of 16 mo, varices recurred in 1 patient in the combined group as compared with 7 patients in the EVL group (P = 0.045). Rebleeding occurred in 3 patients in the EVL group as compared with 1 patient in the combined group (P = 0.687). No patient died in the two groups. No significant differences were observed between the two groups with respect to serious adverse events. CONCLUSION:Intravariceal-mucosal sclerotherapy using small dose of sclerosant is more effective than EVL in decreasing the incidence of variceal recurrence for cirrhotic patients.
RCT Entities:
AIM: To explore the effect of intravariceal-mucosal sclerotherapy using small dose of sclerosant on the recurrence of esophageal varices. METHODS: We randomly assigned 38 cirrhotic patients with previous variceal bleeding and high variceal pressure (> 15.2 mmHg) to receive endoscopic variceal ligation (EVL) and combined intravariceal and esophageal mucosal sclerotherapy (combined group) using small-volume sclerosant. The end-points of the study were rebleeding and recurrence of esophageal varices. RESULTS: During a median follow-up period of 16 mo, varices recurred in 1 patient in the combined group as compared with 7 patients in the EVL group (P = 0.045). Rebleeding occurred in 3 patients in the EVL group as compared with 1 patient in the combined group (P = 0.687). No patient died in the two groups. No significant differences were observed between the two groups with respect to serious adverse events. CONCLUSION: Intravariceal-mucosal sclerotherapy using small dose of sclerosant is more effective than EVL in decreasing the incidence of variceal recurrence for cirrhotic patients.
Authors: A Irisawa; A Saito; K Obara; G Shibukawa; T Takagi; H Shishido; H Sakamoto; Y Sato; R Kasukawa Journal: Gastrointest Endosc Date: 2001-01 Impact factor: 9.427
Authors: Joseph Croffie; Lehel Somogyi; Ram Chuttani; James DiSario; Julia Liu; Daniel Mishkin; Raj J Shah; William Tierney; Louis M Wong Kee Song; Bret T Petersen Journal: Gastrointest Endosc Date: 2007-07 Impact factor: 9.427
Authors: Hind I Fallatah; Haifaa Al Nahdi; Maan Al Khatabi; Hisham O Akbar; Yousif A Qari; Abdul Rahman Sibiani; Salim Bazaraa Journal: World J Hepatol Date: 2012-09-27
Authors: K A Brensing; M Neubrand; J Textor; P Raab; H Müller-Miny; C Scheurlen; J Görich; H Schild; T Sauerbruch Journal: J Hepatol Date: 1998-07 Impact factor: 25.083
Authors: Maria Corina Plaz Torres; Lawrence Mj Best; Suzanne C Freeman; Danielle Roberts; Nicola J Cooper; Alex J Sutton; Davide Roccarina; Amine Benmassaoud; Laura Iogna Prat; Norman R Williams; Mario Csenar; Dominic Fritche; Tanjia Begum; Sivapatham Arunan; Maxine Tapp; Elisabeth Jane Milne; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2021-03-30